Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
This is a Phase I/II , Open-label , Investigator-initiated Trail of Camrelizumab (an Anti-PD-1 Inhibitor), Apatinib (VEGFR2 Inhibitor) and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer The study was designed in two stages, the first stage was the tolerance observation stage, and the second stage was the curative effect expansion stage.

The first part of the study is the Dose-finding Phase designed to establish the safety of Camrelizumab, Apatinib and Nab-paclitaxel at different dose Levels(125 mg/m2, iv. q2w, 150 mg/m2, iv. q2w, 175 mg/m2, iv. q2w or 200 mg/m2, iv. q2w). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses .

This study aims to evaluate the safety and efficacy of Camrelizumab, Apatinib and Nab-paclitaxel in the Second-line treatment of advanced Gastric Cancer.
Advanced Gastric Cancer
DRUG: Camrelizumab, Apatinib and Nab-paclitaxel
MTD /DLT (phase I), Maximum Tolerated Dose/Dose Limiting Toxicity, Within four weeks after administration|ORR(phase II), Overall Response Rate, from the first drug administration up to two years
Incidence of Treatment-Emergent Adverse Events (phase I/II), adverse events/serious adverse events, from the first drug administration to within 90 days for the last drug dose|PFS(phase I/II), Progression-Free-Survival, from the first drug administration up to two years
This trial investigated the safety and efficacy of Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer.